Tuberculosis Exposure, Infection, and Disease Among Children with Medical Comorbidities

Similar documents
Contact Investigation and Prevention in the USA

TB Infection Who is Testing and Treating? TB Control and Elimination: Current Dilemma. Span of TB Control: 2010

Management of Pediatric Tuberculosis in New Jersey

Tuberculosis Screening Protocol For Use In Marin County School Settings

LTBI: Who to Test & When to Treat

10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose

CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT]

Fundamentals of Tuberculosis (TB)

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

TB Nurse Case Management San Antonio, Texas July 18 20, 2012

TB is Global. Latent TB Infection (LTBI) Sharing the Care: Working Together. September 24, 2014

Monitoring & evaluation LTBI management in the Netherlands. Key lessons.

A look at medical factors that increase the risk for TB disease

Latent TB Infection (LTBI) Strategies for Detection and Management

New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents

TB Intensive Houston, Texas. Childhood Tuberculosis Kim Connelly Smith. November 12, 2009

Disclosures. Current Issues and Controversies in Child and Adolescent Tuberculosis 02/24/2016. NSTC 2016 Annual Meeting

Pediatric TB Lisa Armitige, MD, PhD September 28, 2011

Errors in Dx and Rx of TB

Tuberculin Skin Testing

TB Nurse Case Management San Antonio, Texas March 7 9, Pediatric TB Kim Connelly Smith, MD, MPH March 8, 2012

The Epidemiology of Tuberculosis in Minnesota,

Disclosures. TB and CoMorbidities Challenges and Opportunities. Burden of TB. Outline of the lecture. Target testing for TB Infection TB HIV 3/25/2012

Tuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant

TB EPIDEMIOLOGY. Outline. Estimated Global TB Burden, TB epidemiology

Tuberculosis Intensive

has the following disclosures to make:

Chapter 5 Treatment for Latent Tuberculosis Infection

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

Jeffrey R. Starke, M.D. has the following disclosures to make:

Diagnosis Latent Tuberculosis. Disclosures. Case

Contact Follow-Up and Treatment of LTBI in Households of Infectious Cases in Pakistan

Latent Tuberculosis Infection Reporting Instructions for Civil Surgeons Using CalREDIE Provider Portal

Screening and Treatment Recommendations for Persons Exposed to MDR TB

Experience with Pyrazinamide and Rifampin Regimens for Latent TB Infection

Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014

State of the State in TB Control

Tuberculosis: A Provider s Guide to

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB

Disclosures. Public Health Motivation 6/6/2012. The 12-Dose INH-Rifapentine Once-Weekly DOT Regimen: What Next?

Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017

Therapy for Latent Tuberculosis Infection

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016

Tuberculosis Impact in Boston Residents: 2012

Haley Blake Sage Nagai, MPH. Disease Investigation and Intervention Specialists Tuberculosis Treatment and Control Clinic

PREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal

Contact Investigation

Disclosures. Outline. No disclosures or conflicts of interest to report. Special LTBI situations. H t it d id ff t

11/1/2017. Disclosures. Update In Tuberculosis, Indiana Outline/Objectives. Pathogenesis of M.tb Global/U.S. TB Burden, 2016

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis

TB in Corrections Phoenix, Arizona

Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines

INDEX CASE INFORMATION

Please distribute a copy of this information to each provider in your organization.

DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE

Pediatric TB Intensive Houston, Texas October 14, 2013

Annual Tuberculosis Report Oregon 2007

Programmatic management of LTBI : a two pronged approach for ending the TB epidemic. Haileyesus Getahun Global TB Programme WHO/HQ

ESCMID Online Lecture Library. by author

Latent Tuberculosis Best Practices

Diagnosis and Medical Management of TB Disease. Quratulian Annie Kizilbash, MD, MPH March 17, 2015

Detection and Treatment of Tuberculosis in Correctional Facilities: Opportunities and Challenges

Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010

Tuberculosis Surveillance

TB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION

Summary of Key Points WHO Position Paper on BCG Vaccine, February 2018

TB in Foreign Born and High Risk Populations

Tuberculosis Tools: A Clinical Update

Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017

Diagnosis and Medical Management of Latent TB Infection

Treating TB What Happened? All the Patients Have Challenging Co-Morbid Conditions Now!

Diagnosis and Treatment of Tuberculosis, 2011

The Public Health Impact of TB in the Correctional System. Sarah Bur, RN, MPH Federal Bureau of Prisons Infection Prevention and Control Officer

TB Skin Test Practicum Houston, Texas Region 6/5 South September 23, 2014

ANNUAL TUBERCULOSIS REPORT OREGON Oregon Health Authority Public Health Division TB Program November 2012

Pediatric TB Intensive Houston, Texas

Modeling LTBI What are the key issues to consider? Dr Dick Menzies, Montreal Chest Institute, McGill International TB Centre

LATENT TUBERCULOSIS SCREENING AND TREATMENT:

Tuberculosis Education for the Medical Professional

Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015

Diagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015

Tuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013

Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers

Treatment of Tuberculosis

Jennifer Lam MPH candidate 2009 Johns Hopkins Bloomberg School of Public Health. Preceptors: Wendy Cronin, PhD MT(ASCP), Cathy Goldsborough, RN

Disclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None

Community pharmacy-based tuberculosis skin testing

Pediatric TB Theresa Barton, MD

TB Intensive San Antonio, Texas August 7-10, 2012

Background. The global burden of latent M. tuberculosis. More than 2 billion people infected

My heart is racing. Managing Complex Cases. Case 1. Case 1

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

Tuberculosis Elimination Jennifer Flood, MD, MPH Pennan Barry, MD, MPH NAR-NTCA February 25, 2016

LTBI Treatment and Anti TNF alpha

TB and Co-Morbidities Lisa Armitige, MD, PhD September 27, 2011

Dose Counting Exercise Elizabeth Foy, RN, BSN September 8, 2016

TB Intensive Minneapolis, Minnesota September 23-26, 2008

Tuberculosis Screening and Targeted Testing of College and University Students: Developing a Best Practice Approach:

Tuberculosis Elimination

Transcription:

Tuberculosis Exposure, Infection, and Disease Among Children with Medical Comorbidities Andrea T. Cruz, MD, MPH, Omar Merchant, Affan Zafar, and Jeffrey R. Starke, MD Department of Pediatrics February 28, 2014

Background TB is poorly characterized among HIVuninfected immunocompromised children in many settings This results in lack of uniformity (or lack of mention) in many national subspecialty organization guidelines regarding screening for latent TB infection Recent U.S. study found that 25% of children with disease had no identifiable TB risk factors Toussi et al. Clin Infect Dis 2013;57:1318 Winston & Menzies. Pediatrics 2012;130:e1425

Methods Design: Retrospective cohort study Setting: Houston, TX (4.5/100,000) Time period: 1983-2013 Inclusion: 0-18 years of age Classified as exposure, infection, or disease as per standard definitions Exclusion: Immunocompromised Receiving immunosuppressants Pulmonary, hepatic, renal, or hemodynamically significant cardiac disease Mild systemic disease ATS, CDC, IDSA. Am J Respir Crit Care Med 2000;161:S221 Graham et al. J Infect Dis 2012;205:S199

Demographics Variable Subgroup Total (n=69) Disease (n=22) Age Mean (range) 9.5y (2m-18y) 10y (1.2-18y) Gender Female 41% 32% Race/Ethnicity Hispanic 48% 45% Black 29% 27% Asian 17% 23% Country of Origin US 55% 55% Latin America 29% 19% Asia 9% 18% Africa 7% 9% BCG status Received 41% 41%

Comorbidity Total (n=69) Disease (n=22)* Cardiac Hemoglobinopathy Cyanotic heart disease Sickle cell disease 13% 18% 10% 18% Oncologic Solid organ 10% 9% Hematologic 6% 14% GI Crohn s 3% 9% Hepatitis 10% 0% Renal Dialysis 3% 0% Nephrotic 6% 0% Immunologic HIV 4% 0% Primary I.D. 3% 1% Chronic steroids 4% 0% *Diabetes, Krabbe s, juvenile idiopathic arthritis, spina bifida, developmental delay

Exposure 7 children 5 were < 5 yrs old 2 were >5 yrs old but immunosuppressed: HIV Renal transplant recipient Completion: 100% completed 8-10 wks of INH None have progressed to disease

Infection 40 children 25 identified via targeted skin testing 18 foreign birth, 7 foreign travel 9 via contact investigations 6 had no identifiable risk factors Completion: Regimen Completion Rate Complications INH 92% (34/37) 2 children with other hepatic risk factors (antiepileptic use, hepatitis B) developed transaminitis; one mother overdosed her child inadvertently RIF 100% (2/2) - Levoflox/ PZA 0% (0/1) Hepatitis with coagulopathy; later found to have Wilson s disease None have progressed to disease

Disease 22 children (13 confirmed, 9 probable) 20 pulmonary, 1 scrofula, 1 cutaneous TB Only 60% had identifiable risk factors 10 foreign birth, 3 source cases 80% had TST 5mm 4 (18%) died: Age Comorbidity Details 18y 14m Sickle cell, s/p BMT Congenital heart disease Developed disseminated TB after BMT engrafted, died of ARDS; post-mortem blood and lung cultures grew M.tb Developed miliary TB with multiple pulmonary blebs, one of which ruptured, resulting in tension pneumothorax 16y Sickle cell Died of cardiac arrest 3 months into treatment 3y Krabbe s Died of underlying syndrome 2 months into treatment

Conclusions Many children had comorbidities that would not have deemed them at high risk for LTBI Targeted testing would have missed over 40% of children with disease Given high mortality in this small cohort, consideration should be given to integrating LTBI testing into initial and ongoing evaluation of certain pediatric populations

Risk Factor Questionnaire Pediatrics 2001;107:e54

What is a Positive PPD? 5 mm 10 mm 15 mm HIV+ Other immunocompromise 1 Contact with TB case Suspected TB disease in the child Immigrants from highprevalence areas <4 yrs of age Exposed to adults in highrisk categories Other chronic medical conditions 2 Anyone (even if no risk factors) 1: includes chronic corticosteroids, TNF-alpha antagonists 2: includes chronic renal failure, diabetes mellitus, malnutrition, lymphoma 2012 Red Book, Table 3.75